Haq, S. A., Sharma, S. K.. (1392). Pharmacokinetics of ceftazidime in buffalo calves following intravenous and intramuscular administration. , 15(1), 18-22. doi: 10.22099/ijvr.2014.1976
S. A. Haq; S. K. Sharma. "Pharmacokinetics of ceftazidime in buffalo calves following intravenous and intramuscular administration". , 15, 1, 1392, 18-22. doi: 10.22099/ijvr.2014.1976
Haq, S. A., Sharma, S. K.. (1392). 'Pharmacokinetics of ceftazidime in buffalo calves following intravenous and intramuscular administration', , 15(1), pp. 18-22. doi: 10.22099/ijvr.2014.1976
Haq, S. A., Sharma, S. K.. Pharmacokinetics of ceftazidime in buffalo calves following intravenous and intramuscular administration. , 1392; 15(1): 18-22. doi: 10.22099/ijvr.2014.1976
Pharmacokinetics of ceftazidime in buffalo calves following intravenous and intramuscular administration
1MVSc in Veterinary Pharmacology and Toxicology, Department of Pharmacology and Toxicology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana-141004, Punjab, India
2Department of Pharmacology and Toxicology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana-141004, Punjab, India
چکیده
The pharmacokinetic parameters of ceftazidime, a third generation cephalosporin, were investigated in six buffalo calves after single intravenous (IV) and intramuscular (IM) administration at a dose rate of 10 mg/kg body weight. Ceftazidime concentrations in plasma and urine were determined by microbiological assay. Ceftazidime disposition was best fitted by a two-compartmental and a one-compartmental open model with first-order elimination after IV and IM dosing, respectively. After IV administration, distribution was rapid (t1/2α = 0.15 ± 0.01 h) with an area under the ceftazidime plasma concentration/time curve (AUC0-∞) of 253.9 ± 7.8 μg/ml.h and a steady state volume of distribution (Vd(ss)) of 0.18 ± 0.01 L.kg-1. The elimination half life (t½β) and total body clearance were 3.4 ± 0.2 h and 39.5 ± 1.2 ml/kg/h, respectively. Following intramuscular administration, the absorption half life (t1/2ka), peak plasma concentration (Cmax), time to peak plasma concentration (Tmax), AUC0-∞ and bioavailability were 0.25 ± 0.04 h, 45.8 ± 2.7 μg/ml, 0.75 h, 207.9 ± 9.9 μg/ml.h and 81.7 ± 5.9%, respectively. Urinary excretion of ceftazidime was less than 55% 36 h post administration. In vitro plasma protein binding of ceftazidime was 13.1 ± 1.1%. To maintain minimum therapeutic concentration of 4 μg/ml, a satisfactory dosage regimen of ceftazidime in buffalo calves would be 9.4 mg/kg to be repeated at 12 h intervals. In conclusion, ceftazidime (10 mg/kg, IM) shows favorable pharmacokinetic behavior in buffalo calves.